Literature DB >> 6202656

Potentiation of T-lymphocyte function by bleomycin.

D Parker, J L Turk.   

Abstract

Bleomycin, an anti-cancer drug, hitherto thought to have no effect on the immune response, was found to increase contact sensitivity in the guinea pig to 2,4-dinitrofluorobenzene. The drug was given in a single dose (125 mg/kg) on the day of or up to 3 days after sensitization, to achieve this effect. The drug was ineffective if given 3 days before or 4 days after sensitization. In addition, if given 2 or 3 days after sensitization, it caused increased T-cell proliferation in lymph nodes draining the skin sensitization site. It is suggested that the potentiating effect of bleomycin is not on suppressor cell function, as with cyclophosphamide, but might have an effect on local interleukin 2 production, particularly if given when T-cell proliferation is on the increase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202656     DOI: 10.1016/0162-3109(84)90060-2

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

1.  Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

Authors:  M Micallef; M Hosokawa; T Shibata; A Nakane; Z B Yang; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo.

Authors:  T A Abdul Hamied; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Potentiation of interleukin-2 release by anti cancer drugs.

Authors:  J L Turk; T A Abdul Hamied; D Parker
Journal:  Agents Actions       Date:  1989-01

4.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs.

Authors:  M Komatsumoto; M Hosokawa; F Okada; T Okayasu; T Tanabe; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes.

Authors:  L M Webster; A W Thomson
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.